Dr Lotte Knudsen started her medical profession researching laundry detergent that will stay pink dyes from ruining white garments. Many years later, she is the scientist in the back of semaglutide, the lively factor within the blockbuster weight-loss medicine Ozempic and Wegovy – and now, she is hoping to harness the drug to forestall dementia.The self-professed socialist from a small the city outdoor Copenhagen, who relinquished highbrow belongings rights to semaglutide and did not money in on its huge good fortune like Novo Nordisk executives, spearheaded the advance of Ozempic, which used to be to begin with designed to regard sort 2 diabetes. The Danish scientist, pioneered analysis into the drug’s predecessors, culminating in groundbreaking findings about their skill to cut back cognitive decline in dementia sufferers.A number of research she co-authored have exposed compelling proof that Ozempic-like medicine can save you hallmark signs similar to reminiscence loss sooner than inflicting everlasting mind harm.Dr Knudsen believes they may be able to do much more.Of the kind of seven million American citizens with Alzheimer’s as of late, round 81 p.c are estimated to have sort 2 diabetes. The metabolic situation is understood to boost the chance of creating the memory-robbing illness through as much as 77 p.c. 
Dr Lotte Knudsen pioneered analysis into semaglutide and its older cousins, which gave the sector Ozempic and Wegovy, step forward medicine have have helped round 5 million other folks lose weightThe compound she spent years investigating is GLP-1, which mimics a hormone within the mind that regulates urge for food and makes other folks really feel complete.Dr. Knudsen helped expand liraglutide, an artificial model of GLP-1.Since herbal GLP-1 doesn’t final lengthy within the frame, Knudsen and her group added a ‘spacer’ to extend its skill to dissolve within the frame and lend a hand it connect to a protein known as albumin. This allowed it to stick within the frame longer. Development at the foundational paintings executed with liraglutide, Dr Knudsen and her group enthusiastic about making a next-generation GLP-1 analog that would supply enhancements, together with an extended length of motion. Thus, semaglutide, the lively factor in Ozempic and Wegovy, used to be born. Nowadays, semaglutide has been connected to higher results for other folks with center illness and center failure, hypertension, and dementia. Advertised as Ozempic, it’s licensed to regard Sort 2 diabetes however is regularly prescribed off-label for weight reduction.Wegovy is a higher-dose model that’s licensed for weight reduction in individuals who have a frame mass index of a minimum of 30, or in obese other folks with a BMI of 27 or higher, who even have a scientific situation brought about through their weight. The seek for a dementia remedy has now not been going smartly. A part of that is because of a normal lack of expertise of what precisely within the mind reasons signature cognitive decline.Maximum analysis, together with that which has resulted in debatable, dear therapies, has targeted nearly completely on a protein known as beta-amyloid. This protein creates the sticky buildup that clogs up the areas round mind cells.However scientists at the moment are coming to phrases with the perception that they set their points of interest at the fallacious goal. A rising frame of proof posits that twisted fibers that increase inside of mind cells known as tau tangles might be in the back of the dementia.A 2015 find out about printed within the magazine Magazine of Alzheimer’s Illness co-authored through Dr Knudsen investigated how mice given a semaglutide-like compound can be higher ready to stave off cognitive decline.They adopted the mice for 4 months. They all had a predisposition to Alzheimer’s.The mice given the drug liraglutide for 4 months had extra neurons in a key space of the mind (the hippocampus) related to reminiscence, suggesting that the drug would possibly lend a hand maintain mind cells and enhance reminiscence serve as. Dr Knudsen stated final Spring: ‘The effectiveness towards Alzheimer’s has now not but been confirmed, however this can be a speculation that we’re investigating.’Nonetheless accomplishing analysis into liraglutide’s packages, she co-authored a find out about in 2016 that exposed mice with a genetic tendency to expand tau tangles of their brains and motion problems confirmed higher survival when given liraglutide, semaglutide’s older cousin. Mice handled with the drug confirmed a 62 p.c aid in tau tangles in comparison to the untreated mice.A couple of years later, in a find out about printed within the magazine Alzheimer’s & Dementia, Dr Knudsen and associates sampled just about 16,000 other folks and gave one crew a drug in the similar category as Ozempic whilst now not giving the opposite crew the rest.After 3 and a part years, they discovered that the chance of creating dementia used to be 53 p.c decrease within the experimental crew. 
In research in each people and mice, the ones given the category of drug that incorporates Ozempic had slower charges of cognitive decline connected to fewer deposits of damaging proteins within the mind
Your browser does now not give a boost to iframes.
In that very same find out about, they checked out a countrywide cohort of greater than 120,000 other folks with diabetes. Dr Knudsen and fellow scientists adopted them for seven years and 4 months and located that individuals the use of those medicine over a protracted time period had a decrease possibility of creating dementia.Along with the compelling proof pointing to diabetes’ hyperlinks to Alzheimer’s, weight problems is a recognized possibility issue.Analysis has proven a courting between frame mass index (BMI) and mind dimension in other folks across the age of 60, discovering that the upper any person’s BMI, the smaller their mind is.Analysis signifies that mind areas that shrink in Alzheimer’s illness additionally accomplish that in overweight people. Weight problems can scale back resilience to Alzheimer’s-related mind harm, worsening signs and accelerating illness development. It will probably additionally purpose continual irritation, negatively affecting the mind through overstimulating immune cells and destructive nerve cells, linking it to dementia.Ozempic and Wegovy, in the meantime, were proven to cut back an individual’s frame weight through 5 to 20 p.c. At this level, between 5 and 7 million individuals are taking this type of medicine or identical ones from Eli Lilly, and there are early indicators that weight problems charges will have lowered in the USA for the primary time.A CDC record launched in September discovered that 40 p.c of US adults had been overweight from 2021 to 2023, down from 42 p.c from 2017 to 2020.When requested through Pharma Occasions what her purpose for the way forward for those medicine used to be, Dr Knudsen stated: ‘Development new innovation in cognitive impairment (dementia).‘Getting GLP-1 correctly examined in neurodegenerative illness as a result of a large number of science helps its attainable application there.’There are purported downsides to semaglutide despite the fact that. Loads of American citizens have joined a class-action lawsuit alleging that Novo Nordisk, the maker of Ozempic and Wegovy, did not warn its thousands and thousands of keen shoppers concerning the very actual possibility of serious gastrointestinal harm, together with abdomen paralysis, gallbladder problems, colon elimination, and extra, in addition to making deceptive statements concerning the medicine’ protection.It is usually now not transparent but, since the medicine have not been round lengthy sufficient for researchers to have amassed long-term information, whether or not individuals who forestall taking probably the most blockbuster medicine will temporarily regain all the weight they have got misplaced. Dr Knuden’s analysis focal point has modified vastly over time. Ahead of converting the panorama of weight problems remedy, she used to be finding out at the Technical College of Denmark. She started operating with Danish pharmaceutical corporate Novo on a undertaking to discover enzymes that enhance how garments detergent works to each save you colour bleeding and pilling in garments. A analysis mishap all through her investigation into the prevention of dye bleeding, which ended in a stink bomb-like explosion in a lab fridge, coincided with Novo’s acquisition of Nordisk, an insulin-making massive. This transition shifted commercial merchandise to a brand new department, Novozymes, whilst Knudsen’s boss turned into head of a small analysis crew enthusiastic about sort 2 diabetes. Dr Knudsen used to be then introduced into the fold. She turned into a diabetes researcher unintentionally. Repeated efforts to expand compounds that activated GLP-1 receptors failed. However Dr Knudsen’s choice driven the undertaking ahead, laying the groundwork for later developments that turned into a essential breakthroughs.
